



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **Gastrointestinal AEs seen in the POP trial due to SOD mimetic >activity of calmagafodipir? - Authors' Reply EBioMedicine**

**Citation for published version:**

Dear, J 2019, 'Gastrointestinal AEs seen in the POP trial due to SOD mimetic >activity of calmagafodipir? - Authors' Reply EBioMedicine', *EBioMedicine*. <https://doi.org/10.1016/j.ebiom.2019.08.039>

**Digital Object Identifier (DOI):**

[10.1016/j.ebiom.2019.08.039](https://doi.org/10.1016/j.ebiom.2019.08.039)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

EBioMedicine

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.





## Letter

## Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmagafodipir? – Authors' reply



James W. Dear

*Pharmacology, Therapeutics and Toxicology Unit, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK*

The POP Trial Investigators read with interest this letter from Dr. Karlsson [1] regarding the results of our Phase 1 trial [2]. We agree that all safety information from this trial is important for our planning of future trials.

The frequency of gastrointestinal adverse events and serious adverse events in the 4 different treatment groups is already presented in Supplementary Table 2 [2]. These adverse events were nausea, vomiting or abdominal pain – all symptoms that are common after a paracetamol overdose treated with acetylcysteine.

No patient in this trial developed diarrhoea.

### References

- [1] Karlsson JOG. Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmagafodipir? EBioMedicine 2019 [https://www.ebiomedicine.com/article/S2352-3964\(19\)30556-0/fulltext](https://www.ebiomedicine.com/article/S2352-3964(19)30556-0/fulltext).
- [2] Morrison EE, Oatey K, Gallagher B, et al. Principal results of a randomised open label exploratory, safety and tolerability study with calmagafodipir in patients treated with a 12h regimen of N-acetylcysteine for paracetamol overdose (POP trial). EBioMedicine 2019;46:423–30. <https://doi.org/10.1016/j.ebiom.2019.07.013>.

DOIs of original article: <https://doi.org/10.1016/j.ebiom.2019.07.013>, <https://doi.org/10.1016/j.ebiom.2019.08.038>.

E-mail address: [james.dear@ed.ac.uk](mailto:james.dear@ed.ac.uk).

<https://doi.org/10.1016/j.ebiom.2019.08.039>

2352-3964/© 2019 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).